Chronic Myeloid Leukemia in Children: Challenges and Opportunities Based on 7th Dr. I. C. Verma Excellence Award for Young Pediatricians Delivered as Oration on 29th Sept. 2019

被引:3
作者
Bansal, Deepak [1 ]
机构
[1] Postgrad Inst Med Educ & Res, Adv Pediat Ctr, Dept Pediat, Hematol Oncol Unit, Chandigarh, India
关键词
Pediatric; Dasatinib; Nilotinib; Developing country; Survival; Pioglitazone; TYROSINE KINASE INHIBITOR; PROGNOSTIC SCORING SYSTEMS; CLINICAL-PRACTICE; IMATINIB; SURVIVAL; MANAGEMENT; DASATINIB; PREGNANCY; GROWTH; CML;
D O I
10.1007/s12098-020-03234-x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Treatment with tyrosine kinase inhibitors (TKI) is an effective therapy for children and adolescents with chronic phase of chronic myeloid leukemia (CML). For the majority of patients with CML in low- and middle-income countries (LMIC), imatinib is the TKI of choice for reasons of cost, availability, and experience. Children are exposed to therapy for a greater proportion of their lifetime as compared to adults. The adverse effects of prolonged administration of TKI is a subject of ongoing research, as more experience is collected. Therapy with TKI is currently considered to be life-long. Trials on stopping treatment are ongoing to explore if it may be feasible in selected patients, as reported in adults. Growth-failure is a concerning adverse effect. Currently, it seems unclear if the final height attained is within the expected range of the mid-parenteral height and growth standards. Whether the children will achieve a normal height at the end of their growth potential or remain below the predicted range is critical to decide if therapeutic interventions (E.g., growth hormone therapy, or interruption in TKI) should be considered during the period of growth potential. Research on CML in children is at a relatively slow pace, largely due to the rarity of the disease. This provides a unique opportunity for research in population-dense LMICs, as several tertiary centers tend to have a sizable cohort of children and adolescents with CML on follow-up. This narrative summarises the challenges and opportunities in dealing with CML in children, particularly in reference to a center in LMIC.
引用
收藏
页码:443 / 450
页数:8
相关论文
共 55 条
  • [1] Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
    Abou Dalle, Iman
    Kantarjian, Hagop
    Burger, Jan
    Estrov, Zeev
    Ohanian, Maro
    Verstovsek, Srdan
    Ravandi, Farhad
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Cortes, Jorge
    [J]. CANCER MEDICINE, 2019, 8 (15): : 6559 - 6565
  • [2] [Anonymous], 2021, PLYMOUTH M
  • [3] Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group
    Athale, Uma
    Hijiya, Nobuko
    Patterson, Briana C.
    Bergsagel, John
    Andolina, Jeffrey R.
    Bittencourt, Henrique
    Schultz, Kirk R.
    Burke, Michael J.
    Redell, Michele S.
    Kolb, E. Anders
    Johnston, Donna L.
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 (09)
  • [4] Pregnancy among patients with chronic myeloid leukemia treated with imatinib
    Ault, P
    Kantarjian, H
    O'Brien, S
    Faderl, S
    Beran, M
    Rios, MB
    Koller, C
    Giles, F
    Keating, M
    Talpaz, M
    Cortes, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1204 - 1208
  • [5] Bansal D, 2016, PEDIATR BLOOD CANCER, V63, pS10
  • [6] SIOP PODC adapted risk stratification and treatment guidelines: Recommendations for acute myeloid leukemia in resource-limited settings
    Bansal, Deepak
    Davidson, Alan
    Supriyadi, Eddy
    Njuguna, Festus
    Ribeiro, Raul C.
    Kaspers, Gertjan J. L.
    [J]. PEDIATRIC BLOOD & CANCER, 2024, 70 (11)
  • [7] Imatinib has adverse effect on growth in children with chronic myeloid leukemia
    Bansal, Deepak
    Shava, Upender
    Varma, Neelam
    Trehan, Amita
    Marwaha, R. K.
    [J]. PEDIATRIC BLOOD & CANCER, 2012, 59 (03) : 481 - 484
  • [8] Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy
    Berman, Ellin
    Druker, Brian J.
    Burwick, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (12) : 1250 - +
  • [9] Effect of imatinib on growth in children with chronic myeloid leukemia
    Boddu, Deepthi
    Thankamony, Priyakumari
    Guruprasad, C. S.
    Nair, Manjusha
    Rajeswari, Binitha
    Seetharam, Shwetha
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2019, 36 (04) : 189 - 197
  • [10] Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy
    Bonifacio, Massimiliano
    Scaffidi, Luigi
    Binotto, Gianni
    Miggiano, Maria Cristina
    Danini, Marco
    Minotto, Claudia
    Griguolo, Davide
    Marin, Luciana
    Frison, Luca
    D'Amore, Fabio
    Basso, Marco
    Sartori, Roberto
    Tinelli, Martina
    Stulle, Manuela
    Fortuna, Stefania
    Bonalumi, Angela
    Bertoldero, Giovanni
    De Biasi, Ercole
    Ruggeri, Marco
    Semenzato, Gianpietro
    Fanin, Renato
    Pizzolo, Giovanni
    Krampera, Mauro
    Tiribelli, Mario
    [J]. LEUKEMIA RESEARCH, 2018, 74 : 75 - 79